Background. There are several regimens for starting antiretroviral treatment, but it remains unknown whether either of them is more advantageous regarding the time course and magnitude of human immunodeficiency virus (HIV) RNA decay in semen.
Sexual transmission of human immunodeficiency virus type 1 (HIV-1) from infected persons is strongly correlated with HIV-1 concentrations in the genital tract, independently of plasma HIV-RNA levels [1] . One reason why early antiretroviral therapy (ART) is currently recommended independently of CD4 + T-cell counts is to reduce HIV-1 concentrations in the genital tract and therefore the risk of sexual HIV transmission. In fact, the linked HIV transmissions observed in the clinical trials on this issue are more likely to occur during the first months after starting ART, before viral suppression was achieved, or in cases of ART failure [2] [3] [4] [5] .
Currently, there are several recommended and alternative regimens for ART-naive patients, including 2 nucleoside reverse transcriptase inhibitors (NRTIs), plus a third drug from 1 of 3 drug classes: an integrase strand transfer inhibitor (INSTI), a nonnucleoside reverse transcriptase inhibitor (NNRTI), or a boosted protease inhibitor (PI) [6, 7] . These regimens have proven efficacy in controlling viremia, but their activity in the genital tract is less well known, remaining unknown whether a particular regimen is more advantageous regarding the time course and magnitude of decay of HIV in the semen. In this study, we compared the impact of the "third antiretroviral drug" family on the kinetics of HIV-RNA in semen from naive paticipants in whom ART was initiated.
Hospital, Seville, Spain. Participants were asymptomatic treatment-naive adults infected with HIV-1, with CD4 + T cell counts >200/µL, plasma HIV-1 RNA concentrations >1000 and <100 000 copies/mL, seminal plasma (SP) HIV-1 RNA levels >1000 copies/mL, and no primary resistance to any antiretroviral drug. The exclusion criteria were sexually transmitted infections; any active disease at enrollment or during the follow-up, including acute or chronic hepatitis B and/or C; current or past malignancies; treatment with immunomodulatory agents; any laboratory abnormality grade 3-4; or concomitant use of drugs with potential interactions with the prescribed drugs. Participants with plasma HIV-RNA levels >100 000 copies/mL were excluded based on current recommendations for the use of rilpivirine (RPV)-containing regimens [7] . Based on the HIV-RNA level in SP during the screening study visit, study participants were randomized in a 1:1:1 ratio (Epidat 4.1 software) to receive tenofovir disoproxil fumarate (DF) 300 mg plus emtricitabine 200 mg and elvitegravir 150 mg plus cobicistat 150 mg (EVG cobi ) co-formulated as a single tablet regimen (Stribild™), RPV 25 mg co-formulated as a single tablet regimen (Eviplera™), or darunavir 800 mg plus ritonavir 100 mg (DRV rtv) . The participants were instructed to take their drugs in the morning after a standard breakfast and to record the time that they took the medication the previous day. The study was conducted according to the principles of the Declaration of Helsinki and was approved by the Spanish Agency of Medicines and Healthcare Products and the Coordinating Committee on Ethics in Biomedical Research of Andalucía. All participants provided signed informed consent.
Follow-Up, Assessments, and Samples
Assessments were performed at baseline and weeks 1, 2, 4, 6, 8, 12, 18, and 24 and included adverse events, adherence (participant self-report and pharmacy records), hematology and chemistry tests, and CD4 + and CD8 + T-cell counts. At each visit, blood samples for C trough measurement were collected 24 hours (±30 min) after the previous dose; otherwise, the samples were discarded. Participants masturbated to collect semen samples into a dry sterile container about an hour before blood samples were taken. Blood and semen samples were processed within 2 hours after collection. Blood plasma (BP) and SP were separated by centrifugation and stored at −80°C until tested. Additionally, peripheral blood mononuclear cells (PBMCs) were isolated from whole blood collected into cell preparation tubes (Vacutainer CPT, BD, Franklin Lakes, NJ, USA).
Virological Measures
HIV-RNA levels were measured in both BP and SP using realtime polymerase chain reaction (PCR) (COBAS AmpliPrep/ COBAS TaqMan HIV-1 Test, Roche Diagnostics, Basel, Switzerland), with a limit of detection of 20 and 30 copies/mL for BP and SP, respectively. The total cellular-associated HIV-DNA from PBMCs was quantified using a custom TaqMan-based realtime PCR assay for the amplification of nucleotides 761-861 of the LTR-gag HIV gene region, which is highly conserved (91%) among all HIV-1 group-M subtypes, using 2 specific primers, forward 5′-TAGCGGAGGCTAGAAGGAGA-3 and reverse 5′-CCCTGGCCTTAACCGAATT8-3′, and a probe within the selected LTR-gag region 5′-TACCGACGCTCTCGCACCCA-3′ labeled with FAM [8] .
Drug Concentration Determinations
Elvitegravir (EVG), RPV, darunavir (DRV), C trough , BP, and SP concentrations were quantified using a modified and validated liquid chromatography with a tandem mass spectrometry method [9] . The standard curves were highly linear for EVG, RPV, and DRV in BP over the ranges of 25−2500 ng/ mL, 5−1000 ng/mL, and 50−10000 ng/mL, respectively, and 5−500 ng/mL, 0.5−100 ng/mL, and 10−1000 ng/mL, respectively, in SP. The intra-and interassay precision and accuracy were <15% for all drugs in both biological samples.
Efficacy Outcomes
The primary efficacy endpoint was the proportion of participants with undetectable HIV-RNA in SP at week 12 of treatment.
The secondary objectives were to analyze the differences in the HIV-RNA time-weighted mean change in the SP, according to the "third antiretroviral drug" family; measure the drug concentrations in BP and SP and their relationships with SP HIV-RNA kinetics; and compare the dynamics of proviral HIV-DNA from PBMCs in participants according to the "third antiretroviral drug" family. Safety was assessed via analysis of documented adverse events.
Statistical Analyses
Given that the viral kinetics in semen after starting different drug families are not well known, this study was planned as a pilot trial under the assumption that the HIV-RNA decay kinetics in SP would be similar to which occurs in BP: a similar HIV-RNA decay for the RPV and DRV rtv groups but much faster with EVG cobi . Therefore, we assumed that 75% of the participants in the EVG cobi -based regimen would achieve undetectable HIV-RNA in SP at week 12, whereas only 30% of the participants in the other 2 groups would achieve this aim. Thus, to achieve a power of 80% to reject the null hypothesis, using a χ 2 test for 2 independent samples (EVG cobi vs RPV/DRV rtv as a single group) with a level of significance of 5%, a minimum sample size of 23 participants in the reference groups and 11 participants in the EVG cobi group was calculated, with a total estimated sample size of 34 participants (ENE 3.0; e-Biometría, Madrid, Spain). Finally, a total of 36 participants (12 per group) were enrolled. The BP and SP HIV-RNA values were log 10 transformed, and samples with undetectable HIV-RNA were set at 1. All measures were included until an undetectable viral load was achieved in BP or SP. Nonparametric tests (Mann-Whitney U, Kruskal-Wallis, and Wilcoxon signed-rank tests) were used to compare continuous variables, including changes in BP and SP HIV-RNA from baseline between the groups, whereas the χ 2 test and Fisher exact test were used to compare categorical variables. The relationships between continuous variables were assessed using linear regression analyses and Spearman's rank correlation coefficients. A log rank test and Cox regression model were used to assess the time to achieve an undetectable viral load in BP and SP. Statistical analyses were performed using the SPSS version 23.0 (IBM Corp., USA), and P-values <.05 were considered significant.
RESULTS
Between January and December 2015, we screened 40 participants, and 4 of them were ineligible due to SP HIV-RNA <1000 copies/mL (n = 2) or BP HIV-RNA >100.000 copies/mL (n = 2). Therefore, 36 paticipants were enrolled and randomized. All participants completed the study with an ART adherence of 100% and without significant adverse events. There were no significant differences among the three groups in the main baseline characteristics (Table 1) . Overall, median basal HIV-RNA was 4.38 (range, 3.04−4.98) log 10 copies/mL in BP and 3.76 (range, 3.02−5.72) log 10 copies/mL in SP (P < .001), without correlation between both compartments (Spearman ρ = 0.169; P = .326) (Supplementary Figure 1) .
Viral Kinetic Decay
According to study design, no statistically significant differences between the EVG cobi group and the grouped RPV and DRV rtv arm (Table 2 ), but given the unexpected results observed, we describe them for each treatment arm separately. After starting ART, the 3 groups of study participants had similar patterns of viral decay in both BP and SP, with an initial rapid exponential decline during the first days (first phase) followed by a slower second phase lasting weeks. In the 3 groups, the viral decay rates were faster in BP than in SP (P < .001). During the first week, the mean decreases in BP HIV-RNA were 1.97 log 10 copies/mL (range, 0.48−3.20) for the EVG cobi group, 1.91 log 10 copies/mL (range, 1.43−2.83) for the RPV group (P = .729), and 1.22 log 10 copies/mL (range, 0.89−1.68) for the DRV rtv group (P = .01). For SP, these values were 1.44 log 10 copies/mL (range, 0.22−3.44) and 1.29 log 10 copies/mL (range, 0.10−1.96) for the EVG cobi and RPV groups, respectively, (P = .713), and 0.53 log 10 copies/mL (range, 0.09−1.09) for the DRV rtv group (P = .045) (Figure 1 and Supplementary Figure 2) . During the second phase, more participants achieved BP viral suppression at early time points in the EVG cobi group than in the RPV and DRV rtv groups. At week 12, all participants in the EVG cobi group, 8 in the RPV group, and 9 in the DRV rtv group had achieved an undetectable BP viral load. In contrast, the time to achieve an undetectable viral load in SP was similar in the EVG cobi and RPV groups and much slower in the DRV rtv group. At week 12, all participants in the RPV and EVG cobi groups had an undetectable viral load in SP; however, only 7 (58.3%) participants achieved an undetectable SP HIV-RNA in the DRV rtv group (P = .003) (Figure 2 ). At week 24, all participants had negative SP HIV-RNA, except one participant in the DRV rtv group who had 100 copies/mL, despite an undetectable BP HIV-RNA. In a Cox proportional-hazards modeling, in which BP and SP HIV-RNA, CD4
+ T-cell counts, and antiretroviral regimen were included, the only variable associated with viral decay rates in BP and SP was the type of ART (P = .012 and .008, respectively).
Once viral suppression was reached in SP, 4 blip episodes were observed in 4 participants: 2 in the EVG cobi group at week 18 (144 and 125 copies/mL), 1 in the RPV group at week 6 (190 copies/mL), and 1 in the DRV rtv group at week eight (95 copies/ mL). No correlation in the blip episodes between SP and BP HIV-RNA was found (P = .590).
The effect of the "third antiretroviral drug" on PBMC proviral DNA was similar regardless of the treatment group, with mean (range) declines of 1.23 (−0.11 to 1.24), 1.10 (0.18−2.34), and 1.14 (−0.21 to 2.39) HIV-DNA log 10 copies/10 6 PBMCs in the EVG cobi , RPV, and DRV rtv groups, respectively (P = .920). We could not quantify HIV-DNA in semen due to very low amounts of lymphocytes in this fluid. There were no relationships between drug concentrations in BP and the HIV-RNA decay rates in all of the groups and no relationships between drug concentrations in SP and the HIV-RNA decay rates for the EVG and RPV groups. In contrast, the 7 participants who achieved an undetectable viral load in SP at week 12 in the DRV rtv group had an SP DRV concentration ≥150 ng/ mL (median, 191.82 ng/mL; range, 154.59−3285.20), whereas 4 of the 5 participants in which HIV-RNA in SP remained positive and did not have DRV concentrations above this cut-off level (median, 124.41 ng/mL; range, 102.46−1187.05).
DISCUSSION
To our knowledge, this is the first controlled, randomized study comparing the differential effect of antiretroviral drug families on viral kinetics in the SP of treatment-naive HIV-infected patients; most previous studies evaluating the effect of antiretroviral drugs on HIV-RNA in SP were cross-sectional.
In the present study, viral load was lower in SP than in BP, and correlations between the compartments were not observed at baseline or during the follow-up [10] . A biphasic decrease in Figure 1 . Mean viral decay in (A) blood and (B) seminal plasma, by each of the "third antiretroviral drugs." A value of 1 was assigned to the samples with undetectable HIV-RNA. Abbreviations: DRV rtv , darunavir/ritonavir; EVG cobi , elvitegravir/cobicistat; HIV, human immunodeficiency virus; LOD, limit of detection; RPV, rilpivirine. HIV-RNA was observed after treatment initiation for BP [11] and SP, although with a lower decay rate in SP, as previously described for efavirenz [12] . Studies have not compared EVG cobi with RPV and boosted DRV; however, similar to clinical trials comparing EVG cobi with efavirenz and ritonavir-boosted atazanavir [13, 14] , the participants on EVG cobi achieved an undetectable BP viral load earlier than those on RPV or DRV rtv . However, unexpectedly, in SP, the HIV-RNA decay rate in the RPV group was as fast as that in the EVG cobi group, not only during the first phase but also throughout the second phase so that all participants in the RPV and EVG cobi groups reached an undetectable viral load in SP by week 12.
There is only 1 study on the pharmacokinetics in the semen of EVG cobi [15] , RPV [16] , and DRV rtv dosed as 800/100 mg once daily [17] , respectively. The drug concentrations that we observed in SP for EVG cobi and DRV rtv are similar to those previously reported [14, 16] but around 4-fold higher, both in BP and SP, than those in the study by Mora-Peris et al [15] . We do not know the reasons for such differences, but the BP concentrations in the participants were similar to those in other pharmacokinetic studies [18, 19] . We found a close correlation between BP and SP drug concentrations in the 3 groups, although the correlation in the RPV group did not reach statistical significance. In the EVG cobi and RPV groups, there were no relationships between drug concentrations and the HIV-RNA decay rates in BP and SP, suggesting that drug concentrations in SP are well above the minimum effective levels. For both EVG and RPV, the drug concentrations achieved in SP exceeded more than 2-fold the protein binding-adjusted EC 90 for wild-type HIV-1 (45 and 12.1 ng/mL, respectively) [20, 21] . In contrast, only one-third of DRV seminal samples showed concentrations above the protein binding-adjusted EC 90 (200 ng/mL) [22] , which could justify the differences in viral load decay in SP among the groups.
It is difficult to make comparisons with other drugs of the same families tested in other studies; however, the SP/BP penetration ratio and activity of RPV in SP compares at least as well as efavirenz. Efavirenz reached concentrations in SP ≥ 2-fold the protein binding-adjusted EC 90 , despite a median penetration ratio of only 3.4%, and 8 of 9 patients analyzed, with a median basal viral load of 3.69 log 10 copies/mL in SP, achieved an undetectable viral load by day 40 after starting treatment [23, 24] . Unfortunately, there are no such similar data for nevirapine and etravirine. Similarly, the dolutegravir SP/BP penetration ratio is only about 7.5%, but the SP concentrations were also about 2-fold the protein binding-adjusted EC 90 (64 ng/mL), and 14 of 15 patients with a median 3.91 log 10 copies/mL in SP achieved undetectable viral load by week 12 of therapy [25] . No data are available for the comparison of viral kinetics in semen for raltegravir or any protease inhibitor.
The number of blip episodes observed in SP after viral suppression was achieved was similar, regardless of treatment group and the plasma viral load and were not associated with SP drug concentrations. All the episodes showed low-level HIV replication (32 to 215 copies/mL), and the frequency was similar or lower than that observed in participants on other suppressive cART regimens [26] [27] [28] .
Our work has several limitations; one is the small sample size in each group, although this limitation is common to all studies evaluating viral kinetics and drug concentrations in semen. Also, we only quantified HIV-DNA in PBMCs; the measurement of proviral HIV DNA in semen and comparison with that in blood would have provided a more comprehensive analysis of the possible impact of different antiretroviral drug families on cellular HIV reservoir kinetics in this compartment. Besides, these results might not be generalizable because all the participants were men who have sex with men, with chronic HIV infection and viral loads within 1000-100 000 copies/mL. In conclusion, EVG cobi gives rise to a faster viral load decay in plasma than RPV or DRV rtv ; however, if the main reason for starting ART is to reduce the risk of sexual HIV transmission, it seems reasonable to choose EVG cobi or RPV over DRV rtv because both behave similarly and achieve an undetectable viral load in semen much faster than DRV rtv . These results can be related to the better penetration of EVG cobi and RPV than DRV rtv in the male genital tract.
